Revenue growth of 22%, two strategic acquisitions and geographical expansion strengthen the foundation for the years ahead.
Press Release
Copenhagen
Abacus Medicine Group presents another year of record revenue, growth and strategic progress. Revenue grew 22% to EUR 1,818 million, based on a combination of increased sales in both new and existing markets, and an extraordinary performance in our Pharma Wholesale division which achieved 47% organic growth through hospital tenders and new pharmacy customers..
“2025 was a year in which we pursued and completed several long-term investments,” says Flemming Wagner, CEO of Abacus Medicine Group. He continues: “We have strengthened our business portfolio and geographical footprint both organically and through acquisitions. And we have continued to invest in our people and digital capabilities – while remaining firmly committed to our purpose of improving healthcare through better access to medicine.”
| Key figures (In EUR’000) | 2025 | 2024 |
|---|---|---|
|
Revenue |
1,817,637 |
1,486,964 |
|
Gross Profit |
196,919 |
171,022 |
|
Operating profit before depreciations, amortisation and special items (Adjusted EBITDA) |
45,150 |
50,545 |
|
Profit for the year |
7,779 |
17,621 |
|
Revenue growth |
22.2% |
22.9% |
|
Gross margin |
10.8% |
11.5% |
|
Adjusted EBITDA margin |
2.5% |
3.4% |
|
Free cash flow |
-20,009 |
26,436 |
The Group made significant progress under its Access26 strategy, including:
- Geographical expansion with recorded sales in more than 40 countries
- A strengthened market offering in the Pharmaceuticals division following the acquisition of Swiss-based Swiss Cardio Technologies and their innovative cardioplegic solution
- Acquisition of the Belgian parallel importer Medigroup in the Pharma Trading division
- Renovation of the warehouse at full-line wholesaler Pluripharm
- Solid development across all business areas
- Continued investments in employees, leadership development and learning
- Progress in digitalisation and AI, including the opening of a digital hub in Berlin
Continued investments and diversified portfolio will drive future profitability
Following major investments in 2025, reported profitability did not reach 2024 levels, but the investments position the Group for stronger future returns. The Abacus Medicine Group expects to continue the historical double digit organic revenue growth trend in 2026 with an outlook of revenue growth of 12-16%.
The Group’s strategy to expand market share across the EU, combined with continued high levels of investment in digital capabilities, people and business development, is expected to continue to impact EBITDA margins in 2026, predicted to be in the range of 2.2–2.6%.
The Pharma Trading division is expected to continue its growth in both new and existing markets and through Medigroup, while the Pharmaceuticals division is expected to grow with the launch of Swiss Cardio Technologies’ product in select markets.
In 2026, the Group remains focused on organic growth as well as potential acquisitions.
“During 2026, we will initiate the development of our next corporate strategy. With the strong foundation built with recent years’ investments, we are well positioned to deliver solid profitable growth and take the next steps in our continued development,” says Flemming Wagner.
View the full Annual Report 2025 for the Abacus Medicine Group
Contact
Peter Høj, Executive Advisor
Mobile: +45 25 54 26 96, peter.hoj@abacusmedicine.com
Kasper Lytthans, Head of Investor Relations and M&A
Mobile: +45 30 80 89 16, kasper.lytthans@abacusmedicine.com
About the Abacus Medicine Group
The activities of the Abacus Medicine Group are organised in three business units: Pharma Trading, Pharmaceuticals and Pharma Wholesale. The main brands of each business areas are:
- Abacus Medicine – among the leaders in the European market for parallel distribution of medicine.
- Abacus Medicine Pharmaceuticals – partner for pharma and biotech companies launching and commercialising specialty medicines in Europe.
- Pluripharm – operates as a wholesaler and supplies medicine, medical devices, and related services to pharmacies, hospitals and directly to thousands of patients in the Netherlands and Ireland.
The Group numbered 1,759 employees at year-end 2025.